ScienceDaily

Breakthrough PTSD treatment achieves 68% remission rate in clinical trial

A newly FDA-cleared PTSD treatment uses personalized brain mapping and magnetic stimulation to target abnormal brain activity, with a clinical trial reporting a 52% reduction in symptoms and 68% remission. Researchers believe the technology could transform PTSD care and pave the way for more precise treatments for other mental health conditions.

By ScienceDaily

1 min read
Breakthrough PTSD treatment achieves 68% remission rate in clinical trial
AI-generated illustration

Got news to share with the events industry?

Submit a press release or story tip and reach thousands of event professionals.

Get in touch→

More in Medical Science

Related Insights